X

Trial Profile

A Multi-center Phase II Study with Safety Run-in Evaluating the Efficacy and Safety of Ublituximab in Combination with Ibrutinib in Patients with Select B-Cell Malignancies

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 09 Sep 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibrutinib (Primary) ; Ublituximab (Primary)
Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Mantle-cell lymphoma
Focus Adverse reactions
Sponsors TG Therapeutics Inc

Most Recent Events

03 Sep 2019 Status changed from active, no longer recruiting to completed.
10 Jul 2019 Planned End Date changed from 1 May 2019 to 1 Feb 2020.
26 Feb 2019 Planned End Date changed from 1 Nov 2018 to 1 May 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com